《Table 3.Cardiovascular Events during 2-Year Clinical Follow-Up[Case (%) ]》

《Table 3.Cardiovascular Events during 2-Year Clinical Follow-Up[Case (%) ]》   提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《Effectiveness of Integrative Medicine Therapy on Coronary Artery Disease Prognosis: A Real-World Study》


  1. 获取 高清版本忘记账户？点击这里登录
  1. 下载图表忘记账户？点击这里登录
Notes:Including 2 fatal MI cases（1 in each group）.△Including 11 revascularization cases due to MI （2 in the IM group and 9 in the CT group）

The prognostic factors analysis involved 22variants.Table 4 displayed the rough result of logistic regression analysis for these variants，in which IM therapy showed a beneficial tendency for decreasing the incidence of cardiac death or MI events[odds ratio（OR）:0.587；95%confidence interval（CI）:0.251，1.371；P=0.218].

图表编号XD0049340800    严禁用于非法目的
绘制时间2019.01.01
作者ZHAO Kang、TIAN Jin-fan、ZHAO Cong、YUAN Fei、GAO Zhu-ye、LI Li-zhi、LIU Hong-xu、WANG Xian、GE Chang-jiang、LU Shu-zheng
绘制单位Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University—Beijing Institute of Heart, Lung and Blood Vessel Diseases、Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University—Beijing Instit
更多格式高清、无水印（增值服务）

相关图表

  1. 《Table 2 Biological, pharmacokinetic, clinical and endoscopic data at baseline and during follow up》2019.04.14
  2. 《Table 5.IVIG dose and the total types of adverse reactions and intervention during the events.》2019.01.01
  3. 《表6 研究期间患者不良事件发生情况Tab.6 The occurrence of adverse events with patients during the study》2019.02.15
  4. 《表2 2014—2017年药物过敏和皮试相关的不良事件Tab.2 Adverse events related with drug allergy and skin test during 2014—2017》2019.01.15
  5. 《Table 1 Clinical phenotype and results of 9-year follow-up study of OFCD patient》2019.01.05
  6. 《Table 3–Spearman correlation analysis between the microorganisms during the four sampling events (n=44) .》2019.03.15
  7. 《表1 6例儿童骨病导致的股骨颈缺损的临床资料及治疗随访结果Tab.1 Clinical data and treatment follow-up results of femoral neck defects caused by bone》2019.01.19
  8. 《Table 3 Pre-and postoperative clinical data of recurrent cases of PCG at 1-year follow-up within the two types of second》2019.02.18
  9. 《Table 2Univariate and multivariate analysis of risk factors for clinical failure during EUS-TD.》2019.02.15
  10. 《Table 4.Extreme events for ENSO, QBO and solar cycle during 1979–2010》2019.03.01
  11. 《Table 1.Radars in operation during selected precipitation events with a detected bright band (BB) .》2019.01.10
  12. 《表2 随访患者的临床资料Tab.2 Clinical information of follow-up patients》2018.09.19
  13. 《表2 B组病例基本信息、随访结果及治疗转归Tab.2 General information, clinical results and follow-up of Group B》2018.05.19
  14. 《表1 A组病例基本信息、随访结果及治疗转归Tab.1 General information, clinical results and follow-up of Group A》2018.05.19
  15. 《表3 1980—2010年厄尔尼诺和拉尼娜事件Tab.3 El Ni1o and La Ni1a events during 1980-2010》2018.12.31
  16. 《Table 4 Ratios of pollutant concentrations during sand-dust weather events compared to those seen under clear sky condit》2018.10.01
  17. 《表2 门诊随访126名患者临床不良事件发生率Tab.2 Incident of liver-related clinical adverse events in 126 follow-up outpatients[n (%) ]》2018.06.20
  18. 《表6 La Nia现象衰亡期或结束后8个月内发生旱涝急转事件统计Tab.6 Statistics of DWAA events that occurred during decline stages of La Nia or within》2018.01.25
  19. 《Table 5 Adverse events during the study treatment》2018.03.01
  20. 《表2 2组患者随访2年中的医疗费用Tab.2 Medical expenses of patients in two groups during 2-year-follow-up》2018.11.28

随机翻阅

《表2 TROP2与N-cadherin、Vimentin和E-cadherin表达的相关性》 《表4 钢板常温拉伸性能》 《表2 高效液相色谱梯度洗脱程序（Waters Symmetry柱）》 《表4 不同浓度的缓蚀阻垢剂对A3钢在模拟水中的交流阻抗参数》 《表2 引起手术感染危险因素的单因素分析结果》 《表1 不同消解体系酸用量》 《表1 实验样机具体电路参数Tab.1 Detailed circuit parameters of experimental prototype》 《表A1开源用户信息：城市负荷空间分布的聚类群簇分析》 《表1 规划方案：主动配电网中计及网络重构的分布式电源鲁棒规划》 《表1 0 时间和收入中介效应（稳健性检验）》